You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, T-Cell, Peripheral

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

Recruiting
  • Peripheral T Cell Lymphoma
  • Azacitidine Injection
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,

Recruiting
  • Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
  • Guangzhou, Guangdong, China
    Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022

Peripheral T-cell Lymphoma Trial in Tianjin (Lposomal mitoxantrone HCl,Cyclophosphamide,Vincristine,Etoposide and

Not yet recruiting
  • Peripheral T-cell Lymphoma
  • Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jul 13, 2022

Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)

Recruiting
  • Peripheral T Cell Lymphoma
  • Mitoxantrone liposome、Chidamide、Azacitidine
  • Zhejiang, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 9, 2022

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

Minimal Residual Disease in Peripheral T-cell Lymphoma

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Feb 14, 2022

T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

Not yet recruiting
  • T-Cell Lymphoma
  • (no location specified)
Jul 22, 2022

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))

Not yet recruiting
  • NK/T-cell Lymphoma
  • Positron Emission Tomography/Magnetic Resonance (PET/MR)
  • Shanghai, Shanghai, China
    Ruijin Hospital
Dec 14, 2022

Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)

Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
Dec 3, 2021

Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)

Recruiting
  • Treatment
  • Peripheral T-cell Lymphoma
  • liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
  • Beijing, China
  • +4 more
Jun 28, 2022

T Cell Lymphoma Trial (Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen)

Not yet recruiting
  • T Cell Lymphoma
  • Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
  • (no location specified)
Mar 6, 2023

T-cell Lymphoma Trial (Tucidinostat, Azacitidine combined with CHOP)

Not yet recruiting
  • T-cell Lymphoma
  • Tucidinostat, Azacitidine combined with CHOP
  • (no location specified)
Oct 9, 2021

Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Suzhou (Anti-PD-1 mAb, Lenalidomide, Azacitidine)

Recruiting
  • Relapsed/Refractory Peripheral T-cell Lymphoma
  • Anti-PD-1 monoclonal antibody
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 21, 2021

T-Cell Lymphoma Trial (Brentuximab vedotin)

Not yet recruiting
  • T-Cell Lymphoma
  • Brentuximab vedotin
  • (no location specified)
Jun 30, 2022

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)

Not yet recruiting
  • Peripheral T-Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in London (Avelumab)

Completed
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • London, United Kingdom
    University College London Hospital
Oct 1, 2021

Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Mar 4, 2022

Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))

Not yet recruiting
  • Extranodal NK/T Cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 16, 2022

T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory Trial in United States (LB1901)

Active, not recruiting
  • T-Cell Lymphoma
  • +4 more
  • LB1901
  • Rochester, Minnesota
  • +3 more
Feb 15, 2022

ISTODAX® for Intravenous Infusion Drug Use Results Survey-

Recruiting
  • Lymphoma, T-Cell, Peripheral
  • Osaka, Japan
    Nihon Seimei Hospital
Jun 1, 2021

T-cell Lymphoma, Virus, Intravenous Injection Trial (Oncolytic Virus Injection(RT-01))

Not yet recruiting
  • T-cell Lymphoma
  • +2 more
  • Oncolytic Virus Injection(RT-01)
  • (no location specified)
May 18, 2022

Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma

Recruiting
  • Anaplastic Large Cell Lymphoma
  • +19 more
  • Duarte, California
  • +2 more
Aug 15, 2022